Austin Health

Title
Haematological actions of androgens.
Publication Date
2022-04-01
Author(s)
Warren, Annabelle M
Grossmann, Mathis
Subject
erythropoietin
haematocrit
haematopoiesis
iron
testosterone
Type of document
Journal Article
OrcId
0000-0001-8261-3457
0000-0002-7287-6162
DOI
10.1016/j.beem.2022.101653
Abstract
In this review, we discuss the effects on androgens on the haemopoietic system, focussing largely on the effects of testosterone on erythropoiesis. Stimulation of erythropoiesis is one of the most consistent effects of testosterone treatment observed in clinical trials. In men with anaemia this effect can be beneficial. Conversely, erythrocytosis is one of the most common adverse effects of testosterone treatment with a relative risk of 8.14 (95% CI: 1.87-35.40) estimated by a recent meta-analysis of randomised placebo controlled clinical trials. A reduction in haemoglobin is commonly seen in men receiving androgen deprivation therapy for prostate cancer, and in transwomen receiving gender affirming therapy to reduce serum testosterone. While mechanisms by which androgens regulate erythropoiesis are not fully understood, it is likely that effects on erythropoietic progenitor cells and erythropoietin are involved, with secondary effects on iron metabolism. In contrast, whether androgens exert clinically relevant effects on white blood cells and on platelets requires further study.
Link
Citation
Best Practice & Research. Clinical Endocrinology & Metabolism 2022; 36(5): 101653
Jornal Title
Best practice & research. Clinical endocrinology & metabolism

Files:

NameSizeformatDescriptionLink